Research Services Blog

The COVID-19 pandemic has changed the way we interact with our customers. The interactions of the commercial team with the customers and prospects are pushed to be more virtual. And with the pandemic, we are all discussing about the ‘new normal’ where a behavioral change in these interactions are expected to sustain and become a habit.
During these times of virtual interaction, one aspect that we at MedGenome have focused on is developing a platform to manage project logistics and project delivery.

COVID-19 caused by SARS-CoV-2 Virus has emerged as a major challenge with no known vaccine available in the market so far. This pandemic has warranted scaling up of research efforts both by pharma companies and university research centres to develop a viable vaccine. Although there are many promising candidates in the pipeline, none will be available anytime soon making social distancing measures and quarantine as the only effective resort to contain this disease.

Biomarkers are biological indicators of early disease detection (diagnostic), disease progression and outcome (prognostic), and response to therapy (predictive). The inclusion of biomarkers in patient selection has led to superior drug response rates and increased overall survival in pivotal clinical trials. Also, use of biomarkers to select drug sensitive patients have greatly improved the quality of life by improving therapeutic efficacy and reducing toxicity.

It is a miracle of billion-years evolution that vertebrates, including us – the humans, are constantly thwarting attacks from an ever-expanding universe of foreign invaders such as bacteria, viruses and other pathogenic organisms throughout our lifetime. The miracle that makes this happen is our adaptive immune system, comprising of B and T cells, and a host of other regulatory cell-types that function as a central command to activate, mobilize and eventually suppress the army of rogue killers, once the threat is eliminated.